I am Hiroshi Kawamoto of Kyoto University and would like to introduce our company Rebirthel.

Our body contains killer T cells. These cells kill cancer cells and virus-infected cells.

Rebirthel produces killer T cells from iPS cells.

It is an advanced scientific achievement, and we aim to operationalize these killer T cells for patient treatment.

The name of our company, Rebirthel, is a coined word that fused "Rebirth" and "Cell," and it was founded in Kyoto City in October 2019.

We named our company "Rebirthel" because we produce T cells.

Ongoing T-cell therapies take a long time, because they collect cells from cancer patients, expand them, and then return them to the patients. They are also costly.

And because it depends on the quality of T cells of patients, there is the problem of heterogeneity in quality.

On the other hand, with our method using universal iPS cells, we can mass-produce T cells, freeze and store them, and thaw them when needed by patients.

Our therapy is universal, rapid, and low cost, and we can promise high quality.

We are currently preparing a clinical trial for leukemia at Kyoto University.

Our technology can also be applied to viral infections, so we are developing a treatment for the novel coronavirus infection in collaboration with Fujita Medical University.